Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farThe steady progress of targeted therapies, promising advances for lung cancerAfatinib in Non-Small Cell Lung CancerSquamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationThe distinctive nature of adenocarcinoma of the lungThe Evolution of Therapies in Non-Small Cell Lung CancerPersonalized treatment of advanced non-small-cell lung cancer in routine clinical practiceNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceInfluence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIsEfficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancerThe continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lungAfatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?Squamous Cell Cancers: A Unified Perspective on Biology and GeneticsA window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusAfatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma.A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection.Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Nivolumab for treating non-small cell lung cancer.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.Novel therapies for advanced squamous cell carcinoma of the lung.Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
P2860
Q26740529-083CF2C6-7805-4812-82DD-3072B3AB8652Q26745590-6FE52EE4-8EBF-4774-ACC3-EEE9B20F7E49Q26745776-011521CB-AA05-4CB0-AB43-F63967F6F55EQ26746895-89736F8C-3960-402D-B863-85508674B96EQ26749005-CBD2F232-1A11-4113-86C9-1E294916AE94Q26765060-F2993E5C-F7B7-4784-B18B-1EEA1F5E5F37Q26781159-8B377A28-3A3D-433B-BD87-E7B2BEB76381Q26786932-497C4E78-9ACD-4572-A69C-45CAE223181AQ28075800-AED72D7F-747E-4408-B286-A8F4923B3369Q28079320-A7A99142-AA01-4AB7-B53A-EEFCB94281A1Q33653707-06BFA901-330E-4DD8-AD3A-8FAF29C33013Q33704088-2D67CF37-9055-4BF7-8867-D7786F734AFCQ36319739-CAACB582-8E66-49E9-96AF-1A906711F46AQ36352476-4BA27C53-F81C-4827-B35C-402FD653175EQ36545226-1BB5223B-2E75-4321-816E-02D72A10543EQ36594234-6465F95A-3A2D-4AC0-AC1B-05A4DDF3CDC0Q36594244-87BC69CF-0D5F-422F-AFCD-6719DA34FB1CQ36909843-2CB46682-B0D7-4CA2-8EF5-5F21DDDE6534Q37295447-7721FE53-5A65-49FF-9497-0E50FDE6FFE5Q37392573-BDEA7588-5EFA-4870-8151-E62B15C2CA82Q37438480-4D9B1417-59AA-42CC-AFAF-71A2E82001C3Q37578362-F1959ECC-73E3-4D51-B053-43622E8EDC67Q37582758-9AFAC0B8-00AC-4873-B9A3-AE3FAA6667C9Q37598057-D44ABF8B-4D73-4678-898F-CD49E2C66D26Q37637905-485BDFFF-D668-4708-B7CF-464D8E81E405Q37642541-F6C5E1FC-EAC5-4011-A875-E6219A5F7AEEQ37650711-9A1A1677-F20E-4C4E-A2E8-0E0A73C00E0BQ37698613-6D99FB54-9415-4DAF-9E12-3F0D81CE6919Q37721218-5B07E80C-AE03-4207-8595-3A3C1EBC2CCDQ38289406-B582E5DD-EB23-405F-9FDA-65078A5D5EFCQ38629823-101231C5-A9BF-4777-83AE-51472866D30CQ38634988-BD50B611-6A04-4A76-945E-F8A05651941DQ38646686-44921383-AE5C-471B-87FC-F433BB8363ABQ38670719-4438D1EA-C205-4340-BFD0-F3CC439E9221Q38694431-1C4A72C8-5E53-4DF9-8209-45E5672CEDB7Q38730533-B0537B83-C3CB-48EB-9F38-CB4F7A9E969EQ38734978-EEF51E81-C4E8-4683-9487-27365B0C26A1Q38748140-001B4C01-5E9B-4504-9DE5-C0E8B0CCC58FQ38768030-43AD3D82-38B3-476D-8C8D-F4C9696B2563Q38831491-4C7564A9-58F9-4EC9-8947-50C000E65F7E
P2860
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Afatinib versus erlotinib as s ...... ised controlled phase 3 trial.
@en
type
label
Afatinib versus erlotinib as s ...... ised controlled phase 3 trial.
@en
prefLabel
Afatinib versus erlotinib as s ...... ised controlled phase 3 trial.
@en
P2093
P50
P1433
P1476
Afatinib versus erlotinib as s ...... ised controlled phase 3 trial.
@en
P2093
Andrea Ardizzoni
Dolores Isla
Erdem Göker
Glenwood D Goss
Ki Hyeong Lee
Konstantinos Syrigos
LUX-Lung 8 Investigators
Manuel Cobo
Salih Z Guclu
Shirish M Gadgeel
P304
P356
10.1016/S1470-2045(15)00006-6
P577
2015-07-05T00:00:00Z